{"prompt": "['- Durvalumab: 1500 mg by 1-hour IV infusion - 1 cycle (i.e. every 4 weeks)', '- FOLFIRI - one course every 2 weeks:', '-', 'Irinotecan: 150 mg/m\u00b2 by 2-hours IV infusion', '- Folinic acid: 400 mg/m\u00b2 (or 200 mg/m\u00b2 if Elvorine) by 2-hours IV infusion', '- 5-FU bolus: 400 mg/m\u00b2 by 10-minutes IV bolus', '-', 'Continuous 5-FU: 2400 mg/m\u00b2 by 46-hours IV infusion', 'FOLFIRI - every 2 weeks', '5-FU bolus', '400 mg/m\u00b2', 'Every 4 weeks', 'Irinotecan', '150 mg/m\u00b2', 'IV infusion', 'Tremelimumab', 'Durvalumab', 'Folinic acid', '75 mg', '1500 mg', '400 mg/m\u00b2 IV', 'Continuous 5-FU', 'IV infusion', 'IV infusion', 'infusion', '2400 mg/m\u00b2 IV infusion', '(or 200 mg/m\u00b2 if', 'Elvorine)', '1 hour', '1 hour', '2 hours', '46h (Day 1-2)', 'A minimum of 30 minutes should be observed between durvalumab administration and FOLFIRI.', 'Tremelimumab will be administered first; the durvalumab infusion will start approximately 1 hour', '(maximum 2 hours) after the end of the tremelimumab infusion. Standard infusion time for each is 1 hour.', 'In the event that there are interruptions during infusion, the total allowed time should not exceed 8 hours at', 'room temperature per infusion. If there are no clinically significant concerns after the first cycle, then, at the', 'discretion of the investigator, all other cycles of durvalumab can be given immediately after the tremelimumab', 'infusion has finished.', '6.4.2. For the phase II study', '- Tremelimumab: 75 mg by 1-hour IV infusion - 1 cycle (i.e. every 4 weeks) for only 4 cycles', '- Durvalumab: 1500 mg by 1-hour IV infusion - 1 cycle (i.e. every 4 weeks)', '- FOLFIRI - one course every 2 weeks:', '- Irinotecan: 180 mg/m\u00b2 by 2-hour IV infusion', '- Folinic acid: 400 mg/m\u00b2 (or 200 mg/m\u00b2 if Elvorine) by 2-hours IV infusion', '- 5-FU bolus: 400 mg/m\u00b2 by 10-minutes IV bolus', '- Continuous 5-FU: 2400 mg/m\u00b2 by 46-hours IV infusion', 'FOLFIRI - every 2 weeks', '5-FU bolus', '400 mg/m\u00b2', 'Every 4 weeks', 'Irinotecan', '180 mg/m\u00b2 -', 'IV infusion', 'Tremelimumab', 'Durvalumab', 'Folinic acid', '75 mg', '1500 mg', '400 mg/m\u00b2 IV', 'Continuous 5-FU', 'IV infusion', 'IV infusion', 'infusion', '2400 mg/m\u00b2 IV infusion', '(or 200 mg/m\u00b2 if', 'Elvorine)', '1 hour', '1 hour', '2 hours', '46h (Day 1-2)', 'A minimum of 30 minutes should be observed between durvalumab administration and FOLFIRI.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 22 de 123']['Tremelimumab will be administered first; the durvalumab infusion will start approximately 1 hour', '(maximum 2 hours) after the end of the tremelimumab infusion. Standard infusion time for each is 1 hour.', 'In the event that there are interruptions during infusion, the total allowed time should not exceed 8 hours at', 'room temperature per infusion. If there are no clinically significant concerns after the first cycle, then, at the', 'discretion of the investigator, all other cycles of durvalumab can be given immediately after the tremelimumab', 'infusion has finished.', '7. DOSE ADJUSTMENT BASED ON TOXICITY', 'The toxicities requiring dose adjustments will all be evaluated according to the scale NCI-CTCAE v4.0', '(Appendix 8). Dose adjustments based on toxicity are the same for the 1st and 2nd step of the safety run-in phases', 'and randomized phase II study.', '7.1. Criteria that must be met before each subsequent cycle (D1 of each cycle)', 'G-CSF primary prophylaxis in both arms will be at the investigator discretion according to the previous', 'hematological toxicities and the clinical characteristics of the patient.', 'Definition of febrile neutropenia: fever > 38.5 \u00b0C in medullary hypoplasia period (ANC < 500/mm\u00b3', 'Criteria that must to be met before each subsequent course of treatment for chemotherapy:', '-', 'ANC > 1500 /mm\u00b3', '-', 'Platelet count > 100 000/mm1 3', '-', 'Digestive toxicities VI grade 1', 'As long as these criteria have not been met, symptomatic treatment should be optimised and a CBC will be', 'conducted every 7 days until obtaining the required levels. The treatment is delayed until recovering.', 'Concerning administration of durvalumab tremelimumab, patients should not experienced severe immune-', 'related adverse event (see paragraph 7.4).', 'Criteria for stopping treatment:', 'Treatment may be discontinued if the investigator considers that it is necessary, in case of major toxicity which', 'no longer makes it possible to continue treatment, in case of a serious or unexpected event requiring', 'discontinuation of treatment, disease progression, withdrawal of consent, refusal of patient or in case of', 'pregnancy. If treatment is delayed more than 4 courses (56 days), the study treatment will be discontinued, but', 'patient will continue to be followed in the setting of the protocol.', '7.2. Dose adjustment based on toxicities observed during the rest period', 'Dosage adjustments are needed depending on the maximum grade of toxicity observed between courses of', 'treatment. The treatments will only begin when the criteria required before implementation of any new', 'treatment is obtained (see paragraph 7.1).', 'The occurrence of grade 4 toxicity (excluding hematologic toxicities or other manageable toxicity) shall require', 'the permanent discontinuation of the study treatments unless the investigator considers that there is an interest', 'for the patient to continue with the rest of the treatment when the alleged responsibility of the toxicity observed', 'is not deducted. The recourse treatments will be at the discretion of the investigator. In all cases, the patient will', 'continue to be monitored as part of the protocol according to the protocol schedule.', 'If one drug is stopped due to toxicity, other drugs will continue to be administered.', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 23 de 123']\n\n###\n\n", "completion": "END"}